The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...

Qiagen (QGEN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel Brennan from ...